AnaptysBio (ANAB) Q1 2026 earnings summary

Executive summary

• Completed the spin-off of First Tracks Biotherapeutics, retaining royalty management for Jemperli (GSK) and imsidolimab (Vanda), and streamlining operations with limited staff and minimal operating expenses.

• Focus shifted to managing royalty streams and maximizing shareholder value from existing collaborations.

• Litigation with GSK/Tesaro regarding the Jemperli collaboration agreement is ongoing.

• Appointed Chris Murphy as CFO and added Susannah Gray and Owen Hughes to the Board.

Financial highlights

• Collaboration revenue for Q1 2026 was $25.6M, down from $27.8M in Q1 2025, mainly due to lower Vanda license revenue, offset by a 44% increase in Jemperli royalties.

• Net loss for Q1 2026 was $52.9M ($1.84/share), compared to $39.3M ($1.28/share) in Q1 2025, driven by higher G&A and non-cash interest expense.

• Cash, cash equivalents, and investments totaled $286.5M as of March 31, 2026, down from $311.6M at year-end 2025.

• Research and development expenses decreased to $34.0M from $41.2M year-over-year, while general and administrative expenses rose to $26.2M from $14.1M.

• Non-cash interest expense for royalty monetization agreements was $20.9M in Q1 2026, up from $18.1M in Q1 2025.

Outlook and guidance

• Post-separation, research and development and general and administrative expenses are expected to decrease significantly due to reduced headcount and legal costs.

• Existing cash and investments are expected to fund operations for at least the next 12 months.

• Expects to achieve over $390M in annualized Jemperli royalties by 2029, assuming GSK's peak sales guidance of over $2.7B.

• Anticipates paydown of remaining ~$325M non-recourse debt monetization by end of Q2 2027.

• FDA target action date for imsidolimab in GPP is December 12, 2026.